Search

Objective To describe the characteristics of the body components and phase angle of patients with MAFLD according to those different to fibrosis and hepatic steatosis. Material and methods Observational and descriptive study in a cohort of 585 volunteers from our center with MAFLD criteria. The risk of liver fibrosis was determined by APRI, NAFLD score and FIB-4; At an indeterminate and high risk of fibrosis, a transient elastography (Fibroscan) were realize. Bioimpedance body composition analysis (SECA®) was performed. Patients with ET and SECA® registry were included. Bioimpedance body composition analysis (SECA®) was performed. Patients with ET and SECA® registry were included. Results 125 participants (21.4%) were evaluated, age 53.9 ± 13.9 years, 62.1% women, BMI 33.2 ± 5.8 kg / m2. The SECA® analysis showed mean fat mass of 42% ± 7.32 and muscle mass 21.18 kg ± 6.6. The PhA was 5.1 ± 0.69, in women 4.92 ± 0.62 and men 5.41 ± 0.70. PhA in patients without fibrosis was 5,091 vs with fibrosis 5,121, (p = 0.813). In advanced fibrosis, it reported a low value compared to the rest of the groups (p = 0.031). The PhA in S3 was higher compared to S1 and S2 (5.3 vs 4.82, 4.81) (p = 0.027). Conclusions In MAFLD the PhA was lower than the healthy Mexican population. In patients without fibrosis and severe steatosis, PhA rises proportionally to the increase in fat mass and BMI and in advanced liver fibrosis, PhA decreases.

To describe the characteristics of the body components and phase angle (PhA) of patients with MAFLD according to those different to fibrosis and hepatic steatosis.Observational and descriptive study in a cohort of 585 volunteers from our center with MAFLD criteria. The risk of liver fibrosis was determined by APRI, NAFLD score and FIB-4; at an indeterminate and high risk of fibrosis, a transient elastography (Fibroscan®) were realized. Bioimpedance body composition analysis (SECA®) was performed. Patients with ET and SECA® registry were included. Bioimpedance body composition analysis (SECA®) was performed. Patients with ET and SECA® registry were included.125 participants (21.4%) were evaluated, age 53.9±13.9 years, 62.1% women, BMI 33.2±5.8kg/mIn MAFLD, the PhA was lower than the healthy Mexican population. In patients without fibrosis and severe steatosis, PhA rises proportionally to the increase in fat mass and BMI and in advanced liver fibrosis, PhA decreases.